Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, open-label, dose-finding study to evaluate the safety and pharmacokinetics of ONX 0801, a novel alpha-folate receptor-mediated thymidylate synthase inhibitor, in patients with advanced solid tumours.

Next Previous
X
Search
Trial Profile

A phase I, open-label, dose-finding study to evaluate the safety and pharmacokinetics of ONX 0801, a novel alpha-folate receptor-mediated thymidylate synthase inhibitor, in patients with advanced solid tumours.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Sep 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idetrexed (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 31 Mar 2011 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 28 Sep 2009 Onyx Pharmaceuticals has announced the initiation of this trial in a company media release.
    • 01 Jul 2009 Planned initiation date (30 Sep 2009), planned end date (30 Mar 2011), planned number of patients (60), official title, trial locations and lead trial centers and investigator added as reported by ISRCTN: Current Controlled Trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top